Ep. 252, Chapter 2: Commercializing RNAi with Tolga Tanguler

10:50 – 22:56

Tanguler explains how the unique opportunities presented by commercial RNAi drugs can overcome physician skepticism and poor patient adherence. RNAi therapies like Alnylam Pharmaceuticals’ Leqvio (a quarterly subcutaneous injection for hypercholesterolemia) and the experimental Zilebesiran (a semi-annual injection for hypertension) offer high adherence rates (90-95%) due to their infrequent, convenient administration. Additionally, RNAi drugs fit within existing reimbursement structures.